| |
Monday, April 21, 2025 | 12pm ET / 9am PT Join us for an exclusive webinar exploring groundbreaking findings from the DUTRENEO trial, which evaluated the role of predictive biomarkers in guiding neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). Register today. 
|
|
Today’s Big NewsApr 7, 2025 |
|
Access this resource for key insights from industry leaders on the use of in-country liquid biopsy testing for global clinical trials. Country-specific regulations often prevent or delay access to testing results, decreasing population sizes and increasing timing and costs. Download now to see how to overcome these challenges. 
|
|
| By James Waldron GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South Korean company’s tech to bypass the blood-brain barrier. |
|
|
|
By Kevin Dunleavy Gilead and Roche are continuing to lay off employees in California, with each company revealing a recent round of cuts through the state’s Worker Adjustment and Retraining Notification (WARN) program. While Gilead is eliminating 149 positions at its headquarters in Foster City, Roche is letting go of 108 workers at its Molecular Systems Division in Santa Clara. |
By Kevin Dunleavy Viatris has agreed to a settlement worth up to $335 million to resolve opioid-related claims to state and local governments. |
By Andrea Park Tapping into Henry Winkler’s status as a beloved Hollywood icon has majorly paid off for Apellis Pharmaceuticals, whose recent TV commercial for its geographic atrophy drug Syfovre starring the actor once known as Arthur Fonzarelli has been crowned the champion of this year’s Fierce Madness Drug Ad Tournament. |
|
Scaling advanced biotherapeutics is becoming more complex due to the rise of therapies like cell and gene treatments, RNA therapeutics and monoclonal antibody variants. Access this report to discover key strategies to optimize production, ensure compliance and accelerate commercialization. Download now. 
|
|
By Darren Incorvaia As scientists across the U.S. face increasing uncertainty due to funding freezes and mass layoffs at health agencies, German research institute BioMed X is stepping in to offer a lifeline. The institute has opened a matchmaking program to align threatened NIH grants with potential new funders from the pharmaceutical industry. |
By Fraiser Kansteiner On the heels of a recent cost-cutting drive that severed much of AmplifyBio’s R&D capacity, the Ohio-based contract manufacturing and research hybrid has hung up its hat for good. The company attributed the decision to a downturn in the market for early-stage development of cell and gene therapies, which it said stymied its ability to grow. |
By Conor Hale After launching its latest intravascular lithotripsy catheter, designed to punch through difficult blockages in the vessels of the legs, Johnson & Johnson MedTech’s Shockwave Medical division is now studying the same approach in the arteries of the heart. |
By Zoey Becker Rhythm's Imcivree helped patients with obesity due to brain damage lose weight in a phase 3 study. With the trial win, the company is planning regulatory filings for what could be the first therapy approved in the rare disease population. |
By Andrea Park Last year, AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the monthly TV drug ad spending rankings, ultimately leading the pair of immunology meds to take the full-year title for the third year in a row. 2025, however, is already off to a very different start. |
By Nick Paul Taylor Art Garfunkel is breaking the sound of silence around his experience with plaque psoriasis and Sun Pharma's Ilumya. |
By Nick Paul Taylor Lexeo Therapeutics has posted updated data in Friedreich ataxia patients, linking a gene therapy to improvements on outcomes the biotech plans to use as co-primary endpoints in a registrational trial. |
By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Zoey Becker,Kevin Dunleavy In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we dive into our special report ranking the top pharma R&D budgets for 2024. |
|
|---|
|
|
eBook Typical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
Whitepaper Avoid costly mistakes and ensure your clinical development program meets the highest standards by reading WCG’s whitepaper on Imaging Core Labs, Endpoint Adjudication Committees (EAC), and other safety reviews. Sponsored by: WCG |
Research We interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| Accepting Nominations Now |
|
| Accepting Nominations Now |
|
|
| |
|
+(1)+(1).png)
